"NEW SECTION.  Sec. 2   (1) The administrator of the state health care authority shall report to the house of representatives and senate committees on health care, the house of representatives committee on appropriations, and the senate committee on ways and means on the development of the prescription drug purchasing consortium to be established in section 1 of this act. The report shall include, but not be limited to, the following:
     (a) The prospective design of the consortium, including the criteria through which a preferred drug list will be developed, maintained, and disseminated to participants and the means through which the state will restrict access to nonpreferred drugs within the consortium;
     (b) Projected participation in the consortium by units of local government, private entities, labor organizations, and individuals;
     (c) Projected administrative costs of operation of the consortium and estimated enrollment fees and other fees required to support projected administrative costs;
     (d) Status of efforts to identify joint purchasing opportunities with other states;
     (e) Estimated savings to the state and to units of local government through projected participation in the consortium;
     (f) Prospects for circumventing existing private contracts between private health carriers;
     (g) Enrollment in and estimated savings from the pharmacy connections program established under RCW 70.14.050;
     (h) A review of and report on efforts of the pharmaceutical and other industry groups to provide prescription drugs at reduced or no cost; and
     (i) Estimated impacts on private health insurance markets.
     (2) The report must be submitted by January 1, 2006."